-
-
-
-
-
-
-
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Receives European Commission Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
-
-
-
-
-
-
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
-
-
-
-
-
-
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Announces KRYSTAL-12 Trial of KRAZATI Met Primary Endpoint
-
15,747 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

